A blood-based biomarker assay for multiple sclerosis (MS) disease activity provides actionable insights that supplement standard MS evaluations, especially for treatment initiation and de-escalation ...

LONDON — Previous research has shown that providing a clinically definite multiple sclerosis (MS) diagnosis often takes several weeks or even months. But new research suggests that a new "technology ...

A research team at the Medical University of Vienna has developed a blood test that allows the identification of individuals at risk for developing multiple sclerosis (MS) with a high degree of ...

Cerebrospinal fluid (CSF)-based molecular tests can reliably distinguish multiple sclerosis (MS) from other neurological ...

Quanterix Announces Landmark Study Demonstrating Dual GFAP/NfL Blood Test Approach for Personalized Multiple Sclerosis Monitoring Publication in the journal ‘Brain’ confirms complementary roles of the ...

When an insurance denial blocks guest writer Denise Schnieders from getting an MS disease activity test, she decides to fight back.

UCSF is teaming up with Nektar to study NKTR-0165, an experimental antibody that activates the TNFR2 receptor, as a treatment ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min "The whole future of precision ...

Publication in the journal ‘Brain’ confirms complementary roles of the biomarkers for predicting relapse and chronic disability progression in multiple sclerosis (MS) Simoa technology paired with an ...